Tumorigenesis is a complex and dynamic process, consisting of three stages: initiation,
progression, and metastasis. Tumors are encircled by extracellular matrix (ECM) and …

It is well known that genetic mutations can drive drug resistance and lead to tumor relapse.
Here, we focus on alternate mechanisms—those without mutations, such as phenotypic …

Germline mutations in the BRCA2 tumour suppressor are associated with both an increased
lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease …

Despite advances in the treatment of solid tumors, the prognosis of patients with many
cancers remains poor, particularly of those with primary and metastatic brain tumors. In the …

Simple Summary In this review paper, we explore the role of chronic inflammation in the
pathogenesis of prostatic diseases, such as chronic prostatitis, benign prostatic hyperplasia …

Abstract Treatment of prostate cancer (PC a), a leading cause of cancer among males, lacks
successful strategies especially in advanced, hormone‐refractory stages. Some clinical …

Neuroendocrine prostate cancer (NEPC) is an aggressive, androgen independent PCa and
it is detected in patients undergoing androgen deprivation therapy (ADT). Interleukin-6 (IL-6) …

Nerve growth factor (NGF) contributes to the progression of malignancy. However, the
functional role and regulatory mechanisms of NGF in the development of neuroendocrine …

Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary
prostate tumors have relatively few mutations, and only three genes (ERG, PTEN, and …

Abstract 68 Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and
response assessment of prostate cancer. However, due to neuroendocrine differentiation in …